,address1,address2,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationMean,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,225 Franklin Street,26th Floor,Boston,MA,02110,United States,857 246 8998,https://www.pieris.com,Biotechnology,Healthcare,"Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin based drug candidate, elarekibep used for the treatment of asthma; and PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis. The company also develops PRS-344/S09501 2that consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.",127,"{'maxAge': 1, 'name': 'Mr. Stephen S. Yoder J.D.', 'age': 46, 'title': 'CEO, Pres & Director', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 774715, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.324,0.332,0.3075,0.332,0.324,0.332,0.3075,0.332,0.0,0.745504,-1.5600001,817710,817710,3833435,1084410,1084410,0.3054,0.316,1100,1000,30841794,0.162,1.97,0.9287739,0.26562,0.86345,0.0,0.0,USD,-11205199,-0.81444,54480263,98851904,1421826,1465052,1690761600,1693440000,0.014400001,0.14985,0.67917,0.39,0.0146,0.41,0.76097566,1672444800,1703980800,1688083200,-27045000,-0.33,-0.2,2:1,1417996800,-0.337,0.325,NCM,EQUITY,PIRS,PIRS,"Pieris Pharmaceuticals, Inc.","Pieris Pharmaceuticals, Inc.",1420209000,America/New_York,EDT,-14400000,0.312,2.0,buy,54875000,0.555,-34430000,12828000,1.624,1.934,33207000,31.676,0.427,-0.22996001,-0.63738,-27080000,-19589376,-46138000,4.423,-0.64787,-1.03683,-1.1182901,USD,
1,225 Franklin Street,26th Floor,Boston,MA,02110,United States,857 246 8998,https://www.pieris.com,Biotechnology,Healthcare,"Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin based drug candidate, elarekibep used for the treatment of asthma; and PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis. The company also develops PRS-344/S09501 2that consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.",127,"{'maxAge': 1, 'name': 'Mr. Thomas  Bures', 'age': 48, 'title': 'Sr. VP & CFO', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 499378, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.324,0.332,0.3075,0.332,0.324,0.332,0.3075,0.332,0.0,0.745504,-1.5600001,817710,817710,3833435,1084410,1084410,0.3054,0.316,1100,1000,30841794,0.162,1.97,0.9287739,0.26562,0.86345,0.0,0.0,USD,-11205199,-0.81444,54480263,98851904,1421826,1465052,1690761600,1693440000,0.014400001,0.14985,0.67917,0.39,0.0146,0.41,0.76097566,1672444800,1703980800,1688083200,-27045000,-0.33,-0.2,2:1,1417996800,-0.337,0.325,NCM,EQUITY,PIRS,PIRS,"Pieris Pharmaceuticals, Inc.","Pieris Pharmaceuticals, Inc.",1420209000,America/New_York,EDT,-14400000,0.312,2.0,buy,54875000,0.555,-34430000,12828000,1.624,1.934,33207000,31.676,0.427,-0.22996001,-0.63738,-27080000,-19589376,-46138000,4.423,-0.64787,-1.03683,-1.1182901,USD,
2,225 Franklin Street,26th Floor,Boston,MA,02110,United States,857 246 8998,https://www.pieris.com,Biotechnology,Healthcare,"Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin based drug candidate, elarekibep used for the treatment of asthma; and PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis. The company also develops PRS-344/S09501 2that consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.",127,"{'maxAge': 1, 'name': 'Dr. Hitto  Kaufmann Ph.D.', 'age': 51, 'title': 'Sr. VP & Chief Scientific Officer', 'yearBorn': 1971, 'fiscalYear': 2021, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.324,0.332,0.3075,0.332,0.324,0.332,0.3075,0.332,0.0,0.745504,-1.5600001,817710,817710,3833435,1084410,1084410,0.3054,0.316,1100,1000,30841794,0.162,1.97,0.9287739,0.26562,0.86345,0.0,0.0,USD,-11205199,-0.81444,54480263,98851904,1421826,1465052,1690761600,1693440000,0.014400001,0.14985,0.67917,0.39,0.0146,0.41,0.76097566,1672444800,1703980800,1688083200,-27045000,-0.33,-0.2,2:1,1417996800,-0.337,0.325,NCM,EQUITY,PIRS,PIRS,"Pieris Pharmaceuticals, Inc.","Pieris Pharmaceuticals, Inc.",1420209000,America/New_York,EDT,-14400000,0.312,2.0,buy,54875000,0.555,-34430000,12828000,1.624,1.934,33207000,31.676,0.427,-0.22996001,-0.63738,-27080000,-19589376,-46138000,4.423,-0.64787,-1.03683,-1.1182901,USD,
3,225 Franklin Street,26th Floor,Boston,MA,02110,United States,857 246 8998,https://www.pieris.com,Biotechnology,Healthcare,"Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin based drug candidate, elarekibep used for the treatment of asthma; and PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis. The company also develops PRS-344/S09501 2that consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.",127,"{'maxAge': 1, 'name': 'Maria  Kelman', 'title': 'Exec. Director of Investor Relations', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.324,0.332,0.3075,0.332,0.324,0.332,0.3075,0.332,0.0,0.745504,-1.5600001,817710,817710,3833435,1084410,1084410,0.3054,0.316,1100,1000,30841794,0.162,1.97,0.9287739,0.26562,0.86345,0.0,0.0,USD,-11205199,-0.81444,54480263,98851904,1421826,1465052,1690761600,1693440000,0.014400001,0.14985,0.67917,0.39,0.0146,0.41,0.76097566,1672444800,1703980800,1688083200,-27045000,-0.33,-0.2,2:1,1417996800,-0.337,0.325,NCM,EQUITY,PIRS,PIRS,"Pieris Pharmaceuticals, Inc.","Pieris Pharmaceuticals, Inc.",1420209000,America/New_York,EDT,-14400000,0.312,2.0,buy,54875000,0.555,-34430000,12828000,1.624,1.934,33207000,31.676,0.427,-0.22996001,-0.63738,-27080000,-19589376,-46138000,4.423,-0.64787,-1.03683,-1.1182901,USD,
4,225 Franklin Street,26th Floor,Boston,MA,02110,United States,857 246 8998,https://www.pieris.com,Biotechnology,Healthcare,"Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin based drug candidate, elarekibep used for the treatment of asthma; and PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis. The company also develops PRS-344/S09501 2that consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.",127,"{'maxAge': 1, 'name': 'Mr. Frank  Vollmering', 'title': 'VP of HR', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.324,0.332,0.3075,0.332,0.324,0.332,0.3075,0.332,0.0,0.745504,-1.5600001,817710,817710,3833435,1084410,1084410,0.3054,0.316,1100,1000,30841794,0.162,1.97,0.9287739,0.26562,0.86345,0.0,0.0,USD,-11205199,-0.81444,54480263,98851904,1421826,1465052,1690761600,1693440000,0.014400001,0.14985,0.67917,0.39,0.0146,0.41,0.76097566,1672444800,1703980800,1688083200,-27045000,-0.33,-0.2,2:1,1417996800,-0.337,0.325,NCM,EQUITY,PIRS,PIRS,"Pieris Pharmaceuticals, Inc.","Pieris Pharmaceuticals, Inc.",1420209000,America/New_York,EDT,-14400000,0.312,2.0,buy,54875000,0.555,-34430000,12828000,1.624,1.934,33207000,31.676,0.427,-0.22996001,-0.63738,-27080000,-19589376,-46138000,4.423,-0.64787,-1.03683,-1.1182901,USD,
5,225 Franklin Street,26th Floor,Boston,MA,02110,United States,857 246 8998,https://www.pieris.com,Biotechnology,Healthcare,"Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin based drug candidate, elarekibep used for the treatment of asthma; and PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis. The company also develops PRS-344/S09501 2that consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.",127,"{'maxAge': 1, 'name': 'Dr. Shane  Olwill Ph.D.', 'age': 46, 'title': 'Sr. VP & Chief Devel. Officer', 'yearBorn': 1976, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.324,0.332,0.3075,0.332,0.324,0.332,0.3075,0.332,0.0,0.745504,-1.5600001,817710,817710,3833435,1084410,1084410,0.3054,0.316,1100,1000,30841794,0.162,1.97,0.9287739,0.26562,0.86345,0.0,0.0,USD,-11205199,-0.81444,54480263,98851904,1421826,1465052,1690761600,1693440000,0.014400001,0.14985,0.67917,0.39,0.0146,0.41,0.76097566,1672444800,1703980800,1688083200,-27045000,-0.33,-0.2,2:1,1417996800,-0.337,0.325,NCM,EQUITY,PIRS,PIRS,"Pieris Pharmaceuticals, Inc.","Pieris Pharmaceuticals, Inc.",1420209000,America/New_York,EDT,-14400000,0.312,2.0,buy,54875000,0.555,-34430000,12828000,1.624,1.934,33207000,31.676,0.427,-0.22996001,-0.63738,-27080000,-19589376,-46138000,4.423,-0.64787,-1.03683,-1.1182901,USD,
6,225 Franklin Street,26th Floor,Boston,MA,02110,United States,857 246 8998,https://www.pieris.com,Biotechnology,Healthcare,"Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin based drug candidate, elarekibep used for the treatment of asthma; and PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis. The company also develops PRS-344/S09501 2that consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.",127,"{'maxAge': 1, 'name': 'Mr. Prompong  Chaikul', 'age': 35, 'title': 'Chief Supply Chain Officer', 'yearBorn': 1987, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.324,0.332,0.3075,0.332,0.324,0.332,0.3075,0.332,0.0,0.745504,-1.5600001,817710,817710,3833435,1084410,1084410,0.3054,0.316,1100,1000,30841794,0.162,1.97,0.9287739,0.26562,0.86345,0.0,0.0,USD,-11205199,-0.81444,54480263,98851904,1421826,1465052,1690761600,1693440000,0.014400001,0.14985,0.67917,0.39,0.0146,0.41,0.76097566,1672444800,1703980800,1688083200,-27045000,-0.33,-0.2,2:1,1417996800,-0.337,0.325,NCM,EQUITY,PIRS,PIRS,"Pieris Pharmaceuticals, Inc.","Pieris Pharmaceuticals, Inc.",1420209000,America/New_York,EDT,-14400000,0.312,2.0,buy,54875000,0.555,-34430000,12828000,1.624,1.934,33207000,31.676,0.427,-0.22996001,-0.63738,-27080000,-19589376,-46138000,4.423,-0.64787,-1.03683,-1.1182901,USD,
7,225 Franklin Street,26th Floor,Boston,MA,02110,United States,857 246 8998,https://www.pieris.com,Biotechnology,Healthcare,"Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin based drug candidate, elarekibep used for the treatment of asthma; and PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis. The company also develops PRS-344/S09501 2that consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.",127,"{'maxAge': 1, 'name': 'Dr. Florian  Witte Ph.D.', 'title': 'VP and Head of Alliance Management & Early Project Leadership', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.324,0.332,0.3075,0.332,0.324,0.332,0.3075,0.332,0.0,0.745504,-1.5600001,817710,817710,3833435,1084410,1084410,0.3054,0.316,1100,1000,30841794,0.162,1.97,0.9287739,0.26562,0.86345,0.0,0.0,USD,-11205199,-0.81444,54480263,98851904,1421826,1465052,1690761600,1693440000,0.014400001,0.14985,0.67917,0.39,0.0146,0.41,0.76097566,1672444800,1703980800,1688083200,-27045000,-0.33,-0.2,2:1,1417996800,-0.337,0.325,NCM,EQUITY,PIRS,PIRS,"Pieris Pharmaceuticals, Inc.","Pieris Pharmaceuticals, Inc.",1420209000,America/New_York,EDT,-14400000,0.312,2.0,buy,54875000,0.555,-34430000,12828000,1.624,1.934,33207000,31.676,0.427,-0.22996001,-0.63738,-27080000,-19589376,-46138000,4.423,-0.64787,-1.03683,-1.1182901,USD,
